Immunovant Inc (IMVT) — Strategic Asset Allocation Index

Latest as of June 2023: 0.1%

Immunovant Inc (IMVT) has a Strategic Asset Allocation Index of 0.1% as of June 2023. Strategic assets (PP&E of $325.00K plus long-term investments of $-) total $325.00K, measured against net assets of $299.87 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See net asset quality index of Immunovant Inc to measure how much of total assets are equity-financed.

SAAI

0.1%
Strategic Assets / Net Assets

Strategic Assets

$325.00K
PP&E + LT Investments

PP&E

$325.00K
USD

Net Assets

$299.87 Million
USD

Immunovant Inc Strategic Asset Allocation Index (2019–2023)

This chart shows how Immunovant Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2019 to 2023. As of June 2023, the index stands at 0.1%, representing strategic assets of $325.00K against net assets of $299.87 Million USD. For live market cap and overall valuation, see Immunovant Inc stock valuation.

Annual Strategic Asset Allocation Index for Immunovant Inc (2019–2023)

The table below presents the year-by-year Strategic Asset Allocation Index for Immunovant Inc from 2019 to 2023, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Immunovant Inc book value and equity for net asset value and shareholders' equity analysis.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2023 0.1% $333.00K $333.00K $- $362.49 Million ▲ +0.0 pp
2022 0.1% $330.00K $330.00K $- $469.82 Million ▲ +0.0 pp
2021 0.1% $201.00K $201.00K $- $391.48 Million ▼ 0.0 pp
2020 0.1% $65.00K $65.00K $- $94.07 Million ▼ -219.9 pp
2019 219.9% $54.00K $54.00K $- $24.55K
pp = percentage points